BIOFRONTERA AG (B8FK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:B8FK - DE000A4BGGM7 - Common Stock
2.7 EUR
-0.02 (-0.74%)
B8FK gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. The financial health of B8FK is average, but there are quite some concerns on its profitability. B8FK has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
B8FK had negative earnings in the past year.
B8FK had a positive operating cash flow in the past year.
In the past 5 years B8FK reported 4 times negative net income.
In the past 5 years B8FK reported 4 times negative operating cash flow.
1.2 Ratios
B8FK has a worse Return On Assets (-12.27%) than 75.00% of its industry peers.
B8FK's Return On Equity of -18.00% is on the low side compared to the rest of the industry. B8FK is outperformed by 73.21% of its industry peers.
B8FK has a worse Return On Invested Capital (0.59%) than 66.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.27% | ||
| ROE | -18% | ||
| ROIC | 0.59% |
ROA(3y)-50.22%
ROA(5y)N/A
ROE(3y)-80.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 0.56%, B8FK is doing worse than 66.07% of the companies in the same industry.
B8FK has a better Gross Margin (78.43%) than 76.79% of its industry peers.
B8FK's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.56% | ||
| PM (TTM) | N/A | ||
| GM | 78.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so B8FK is destroying value.
Compared to 1 year ago, B8FK has more shares outstanding
The debt/assets ratio for B8FK has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -5.06, we must say that B8FK is in the distress zone and has some risk of bankruptcy.
B8FK's Altman-Z score of -5.06 is on the low side compared to the rest of the industry. B8FK is outperformed by 82.14% of its industry peers.
The Debt to FCF ratio of B8FK is 0.33, which is an excellent value as it means it would take B8FK, only 0.33 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of B8FK (0.33) is better than 98.21% of its industry peers.
B8FK has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
B8FK's Debt to Equity ratio of 0.01 is amongst the best of the industry. B8FK outperforms 91.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.33 | ||
| Altman-Z | -5.06 |
ROIC/WACC0.08
WACC7.13%
2.3 Liquidity
A Current Ratio of 2.47 indicates that B8FK has no problem at all paying its short term obligations.
The Current ratio of B8FK (2.47) is better than 78.57% of its industry peers.
A Quick Ratio of 1.81 indicates that B8FK should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.81, B8FK belongs to the top of the industry, outperforming 82.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
The earnings per share for B8FK have decreased by -8.46% in the last year.
B8FK shows a small growth in Revenue. In the last year, the Revenue has grown by 7.14%.
Measured over the past years, B8FK shows a decrease in Revenue. The Revenue has been decreasing by -9.04% on average per year.
EPS 1Y (TTM)-8.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.5%
Revenue 1Y (TTM)7.14%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%-14.4%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for B8FK. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 24.65, the valuation of B8FK can be described as rather expensive.
64.29% of the companies in the same industry are cheaper than B8FK, based on the Price/Forward Earnings ratio.
B8FK is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.65 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as B8FK.
Based on the Price/Free Cash Flow ratio, B8FK is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.07 | ||
| EV/EBITDA | 15.56 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
B8FK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:B8FK (11/21/2025, 7:00:00 PM)
2.7
-0.02 (-0.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.23%
Ins Owner ChangeN/A
Market Cap16.42M
Revenue(TTM)23.22M
Net Income(TTM)-2.70M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.65 | ||
| P/S | 0.71 | ||
| P/FCF | 10.07 | ||
| P/OCF | 8.83 | ||
| P/B | 1.07 | ||
| P/tB | 1.07 | ||
| EV/EBITDA | 15.56 |
EPS(TTM)-0.45
EYN/A
EPS(NY)0.11
Fwd EY4.06%
FCF(TTM)0.27
FCFY9.93%
OCF(TTM)0.31
OCFY11.33%
SpS3.82
BVpS2.53
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.27% | ||
| ROE | -18% | ||
| ROCE | 0.84% | ||
| ROIC | 0.59% | ||
| ROICexc | 0.59% | ||
| ROICexgc | 0.59% | ||
| OM | 0.56% | ||
| PM (TTM) | N/A | ||
| GM | 78.43% | ||
| FCFM | 7.02% |
ROA(3y)-50.22%
ROA(5y)N/A
ROE(3y)-80.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
F-Score6
Asset Turnover1.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.33 | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 23.96% | ||
| Cap/Sales | 0.99% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 170.64% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | -5.06 |
F-Score6
WACC7.13%
ROIC/WACC0.08
Cap/Depr(3y)90.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.5%
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.14%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%-14.4%
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.98%
OCF growth 3YN/A
OCF growth 5YN/A
BIOFRONTERA AG / B8FK.DE FAQ
What is the ChartMill fundamental rating of BIOFRONTERA AG (B8FK.DE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to B8FK.DE.
What is the valuation status for B8FK stock?
ChartMill assigns a valuation rating of 3 / 10 to BIOFRONTERA AG (B8FK.DE). This can be considered as Overvalued.
What is the profitability of B8FK stock?
BIOFRONTERA AG (B8FK.DE) has a profitability rating of 1 / 10.
Can you provide the financial health for B8FK stock?
The financial health rating of BIOFRONTERA AG (B8FK.DE) is 6 / 10.